Gilead Sciences, Inc. (GILD)

66.77
0.09 0.13
NASDAQ
Prev Close 66.86
Open 67.09
Day Low/High 66.52 / 67.19
52 Wk Low/High 56.56 / 73.34
Volume 988.86K
Exchange NASDAQ
Shares Outstanding 1253.81B
Market Cap 83.88B
P/E Ratio 68.31
Div & Yield N.A. (N.A)
Amazon's HQ2, Cancer Therapy Approved: Thursday's Top Stories

Amazon's HQ2, Cancer Therapy Approved: Thursday's Top Stories

Today's Top Stories: Amazon's deadline to submit a proposal to build a new headquarters is today, Gilead shares are jumping as a result of the FDA's approval of a cancer treatment, today marks the 30th anniversary of Black Monday.

Dow Powers to New Record, Nears 23,000

Dow Powers to New Record, Nears 23,000

The Dow, the Nasdaq and the S&P 500 all reached new record highs even though drug stocks were under pressure following comments by President Trump.

My Takeaways and Observations

"While options can give market participants the protection they are intended to provide, they can also increase the degree of a counter move, once it gets going, as those who wrote the protection scramble to unwind their own exposure." -- Kass Diary...

Why Is Flexion Falling, and Other Questions

Why Is Flexion Falling, and Other Questions

The first part of Flexion's decline can be attributed to some profit taking.

My Takeaways and Observations (Early Afternoon Edition)

"Why make trillions when we can make billions?" -- Dr. Evil I started the day with a multi-part series, "Sell FANG."  Here, here and here.  A Bull Market in Complacency -- why volatility is low and corrections are non existent.   Auction Action.   N...

Some Weak Names Today

An old trading dictim is that you might consider selling or shorting stocks that are in the red when the market is broadly in the green (and vice versa).   Some conspicuous stocks that are weak today include Comcast , Gilead , Sprint , and Lilly .

Upgrade Confirms Gilead's Price Strength

Upgrade Confirms Gilead's Price Strength

But is it too late?

Getting Bullish on Gilead

Getting Bullish on Gilead

I'm setting up a risk reversal to either buy the stock lower or participate in the upside.

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Today's breakout move in the stock is a highlight of the surging sector.

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Today's breakout move in the stock is a highlight of the surging sector.

Cramer: There Should Be More Takeovers Where These Came From

Cramer: There Should Be More Takeovers Where These Came From

Buying's good for the acquirers, which should give other companies ideas.

Gilead Sciences Breaks Out

Gilead Sciences Breaks Out

With stock back up to $80, it's time to adjust the parameters.

Biotech M&A: Who's Next After Gilead-Kite?

Biotech M&A: Who's Next After Gilead-Kite?

Prospects for acquisition activity in the sector are improving.

Cramer: Rebuilding After Hurricane Harvey Will Be Faster Than After Katrina

Cramer: Rebuilding After Hurricane Harvey Will Be Faster Than After Katrina

That would mean that there is the chance for a comeback here of some note.

Bears Still Can't Execute in the 'Red Zone'

Bears Still Can't Execute in the 'Red Zone'

Monday's action failed to change the overall character of the market

My Takeaways and Observations

"Yeah, well, that's just, like, your opinion, man." -- The Dude, The Big Lebowski Strikes and gutters today -- in a market characterized by winners and losers and weakening breadth. Ups and downs.    Amazon's shares may be signaling there is no fun,...

Cramer: Harvey's Not an Issue for the Markets, the iPhone Is

Cramer: Harvey's Not an Issue for the Markets, the iPhone Is

This market is focused on Apple and Gilead's planned acquisition of Kite.

Jim Cramer on Expedia, Uber, General Electric, Procter & Gamble, Western Digital, Gilead Sciences, Kite Pharma, Apple, Amazon, Whole Foods and Best Buy

Jim Cramer on Expedia, Uber, General Electric, Procter & Gamble, Western Digital, Gilead Sciences, Kite Pharma, Apple, Amazon, Whole Foods and Best Buy

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Monday's trending stocks

Gilead's Gain on Kite Acquisition Doesn't Make Sense

For the life of me I don't see why Gilead Sciences'  shares should respond very positively to the $13 billion acquisition of Kite Pharmaceutical . On Fast Money it is being argued that the takeover is anti-dilutive against cash. So what? It signals ...

Jim Cramer Reacts to the Gilead Sciences-Kite Pharma Acquisition

Jim Cramer Reacts to the Gilead Sciences-Kite Pharma Acquisition

Gilead is acquiring Kite Pharma.

Kite Takeover by Gilead Lifts Biotech Stocks

Kite Takeover by Gilead Lifts Biotech Stocks

The key to dealing with this environment is to keep an open mind.

After a Long Absence, the Gilead Bull Is Back

After a Long Absence, the Gilead Bull Is Back

In the past three months, prices have bottomed.

Here's Why I'm Valuing Value Over Growth

Here's Why I'm Valuing Value Over Growth

Multiples have become quite rich and dysfunction in Washington could end up biting the markets.

Gilead Solidly Higher; Markets in Narrow Range

Markets continue to trade in a very narrow range this Friday, commentary on the Daily Diary is certainly more active than equities today! Most major indices remain slightly down as they have been pretty much since the opening bell. The Dow has just ...

Biotech Bucking the Trend

Coming up on the two-hour mark on trading. The market is down slightly down across the board, with Nasdaq being affected by disappointing results from Starbucks and Amazon . The failure to even getting a "skinny" repeal and replacement of the Afford...

Now Up to the Plate, Today's Pinch Hitter, Bret Jensen!

It is good to be sitting in for Doug Kass here on the Daily Diary as we look to end the trading week on a positive note. It is also good to see the Yankees start to win close games again after losing so many of them in the weeks leading into the All...

Another Day - Another Busy Slate of Earnings

Another Day - Another Busy Slate of Earnings

Ford Motor Co. leads a list of notable earnings reports being released throughout the day on Wednesday

The Worm Has Turned in Biotech's Favor

The Worm Has Turned in Biotech's Favor

But this needs to heat up again for the sector to rally in a big way.

The Worm Has Turned in Biotech's Favor

The Worm Has Turned in Biotech's Favor

However, it will take acquisition activity to heat up again for the sector to rally in a big way.